ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 85 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $141,000 | +131.1% | 21,811 | -41.8% | 0.02% | +114.3% |
| Q2 2020 | $61,000 | -16.4% | 37,447 | -3.3% | 0.01% | 0.0% |
| Q4 2019 | $73,000 | +23.7% | 38,710 | -28.6% | 0.01% | +40.0% |
| Q3 2019 | $59,000 | -67.8% | 54,181 | -35.1% | 0.01% | -54.5% |
| Q2 2019 | $183,000 | +161.4% | 83,539 | +610.5% | 0.01% | +175.0% |
| Q1 2019 | $70,000 | – | 11,758 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |